CASTLE ROCK, Colo., Feb. 14 /PRNewswire-FirstCall/ -- AspenBio Pharma, Inc. (Nasdaq: APPY) an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for animals and humans, has been invited to present at the 20th Annual Roth Capital Partners Growth Stock Conference. The conference will be held February 18-21, 2008 at the Ritz Carlton Laguna Niguel in Dana Point, California. Roth Capital Partners Stock Conferences are one of the largest in the nation for micro and small-cap companies in technology, healthcare, financial services and consumer products sectors. More than 1,000 institutional investors are expected to attend. AspenBio's president and CEO, Richard Donnelly, is scheduled to present on Tuesday, February 19 at 3:00 PM Pacific Time (6:00 PM Eastern Time), followed by a break out session and one-on-one meetings. A simultaneous Webcast will be available at http://www.wsw.com/webcast/roth16/appy/. For more information on the Roth conference, please visit the conference website at http://rothconference.com or call the conference desk at 800-678-9147. For media inquiries and press credentials only call 949-720-5700. About Roth Capital Partners, LLC With corporate headquarters in Newport Beach, California and offices in strategic locations in the Western United States and Shanghai, China, Roth Capital Partners, LLC is a full service investment bank serving corporate and institutional clients throughout the world. Offering a wide array of investment banking services including: initial public offerings, follow-ons, PIPEs, private placements, mergers and acquisitions, investment research, and institutional sales and trading, the firm is perhaps best known for finding, funding and fostering the growth of emerging companies. It is a member of the Financial Industry Regulatory Authority, Inc. ("FINRA"), and the Securities Investor Protection Corporation (SIPC). Visit the Roth Capital Partners website at http://www.rothcp.com. About AspenBio Pharma, Inc. AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to the discovery; development, manufacture, and marketing of novel proprietary products, including those that enhance the reproductive efficiency of animals and that have large worldwide market potential. The company was originally formed to produce purified proteins for diagnostic applications and has become a leading supplier of human hormones to many of the nation's largest medical diagnostic companies and research institutions. The company has successfully leveraged this foundational science and technology expertise to rapidly develop an enviable late-stage pipeline of several novel reproduction hormone analogs for wide-ranging therapeutic use initially in bovine and equine species. AspenBio Pharma continues to advance the development and testing of its two first-generation blood-based human diagnostic tests designed to rapidly help diagnose or rule out appendicitis in patients complaining of abdominal pain. For more information, go to http://www.aspenbiopharma.com.
Investor Relations: Liolios Group, Inc. Ron Both Tel 949-574-3860 email@example.com
SOURCE AspenBio Pharma, Inc.